Thinking of joining a study?

Register your interest

Become a volunteer?

Clinical trials

2719 results

Sort By:

Walk With Me (WWM) for Perinatal Grief

Study ID: NCT07011940
Start Date: 2026-01-01
End Date: 2027-08-31
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

300

Intervention / Treatment

Along With Me

Peer Guide

Sponsor

Oregon Research Behavioral Intervention Strategies, Inc.

Source: clinicaltrials.gov

Share:
Add to list

REstoring Flow by REvascularization with Submaximal Angioplasty in Hemodynamic IntraCranial Atherosclerotic Stenosis

Study ID: NCT03729817
Start Date: 2026-10
End Date: 2030-10-31
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

159

Intervention / Treatment

Submaximal balloon angioplasty

Sponsor

Case Western Reserve University

Source: clinicaltrials.gov

Share:
Add to list

Improving Healing in Children After Tooth Extraction Using Laser Therapy or Hyaluronic Acid

Study ID: NCT07205640
Start Date: 2025-12-01
End Date: 2026-12-01
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

36

Intervention / Treatment

Low-Level Laser Therapy

Hyaluronic Acid (HA)

Sponsor

Cairo University

Source: clinicaltrials.gov

Share:
Add to list

A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

Study ID: NCT06890338
Start Date: 2025-11-24
End Date: 2030-02
Study Type

Interventional

Study Phase

Phase2

No. of Participants

140

Intervention / Treatment

Carboplatin

Mirvetuximab Soravtansine

bevacizumab

Sponsor

AbbVie

Source: clinicaltrials.gov

Share:
Add to list

Retifanlimab and Ruxolitinib In Solid Malignancies

Study ID: NCT07219576
Start Date: 2025-12
End Date: 2029-12
Study Type

Interventional

Study Phase

Phase2

No. of Participants

40

Intervention / Treatment

Ruxolitinib

Retifanlimab

Sponsor

University of California, San Diego

Source: clinicaltrials.gov

Share:
Add to list

The Purpose of This Study is to Evaluate the Safety and Tolerability of X/T+X-EC in Participants With Alzheimer's Disease Who Are Currently Treated With Lecanemab.

Study ID: NCT07212062
Start Date: 2025-12-01
End Date: 2028-12-30
Study Type

Interventional

Study Phase

Phase2

No. of Participants

60

Intervention / Treatment

X/T + X-EC

Placebo

Lecanemab 10 mg/kg

Sponsor

Neurology Office of South Florida

Source: clinicaltrials.gov

Share:
Add to list

Biological and Clinical Underpinnings of Postoperative Pain - Colorectal Surgery

Study ID: NCT07219160
Start Date: 2026-02-01
End Date: 2030-08
Study Type

Observational

Study Phase

Not Applicable

No. of Participants

128

Intervention / Treatment
Sponsor

University of Alabama at Birmingham

Source: clinicaltrials.gov

Share:
Add to list

Peer-led Implementation of TB-HIV Education and Adherence Counseling in Uganda

Study ID: NCT05917210
Start Date: 2026-01-15
End Date: 2028-03-31
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

1920

Intervention / Treatment

Standard TB-EC

Peer navigation strategy for TB-EC

Sponsor

Yale University

Source: clinicaltrials.gov

Share:
Add to list

Toddler Biomarker of Nutrition Study

Study ID: NCT05855824
Start Date: 2026-01-01
End Date: 2028-04-30
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

150

Intervention / Treatment

Applesauce Pouch

Fruit-vegetable puree blend

Sponsor

Baylor College of Medicine

Source: clinicaltrials.gov

Share:
Add to list

Brain Uptrain to Improve Learning and Development

Study ID: NCT06638801
Start Date: 2026-02
End Date: 2031-06
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

188

Intervention / Treatment

Coach-led caregiver-implemented early literacy and developmental programming

Reach Out and Read Training

Sponsor

University of Alabama at Birmingham

Source: clinicaltrials.gov

Share:
Add to list